FOR RESEARCHERS
Coming Soon: RRP-ALSF Early Career Investigator (ECI) Grant
Application Deadline: December 2026
The RRP-ALSF ECI Grant Program supports early-career scientists focused on inherited hematologic malignancy predisposition disorders, particularly RUNX1-FPD. This program provides funding to advance innovative research aimed at intercepting disease-associated processes that lead from a premalignant state to overt hematologic malignancy in RUNX1-FPD patients.
Click below to learn more about past ECI Grant recipients and their funded research projects:
Funded Research Portfolio Overview
Our Research Partners
RRP Research Impact
RRP Cancer Interception/ Prevention Research Roadmap
Our roadmap is simple. We only invest in research that brings us one step closer to our end goal. We understand that discovering medicines requires the right tools (i.e. disease models and laboratory reagents) and the right datasets (i.e. patient clinical and genomic data, as well as patient biospecimens). We have defined 4 rational therapeutic approaches to preventing blood cancer:
1) selectively targeting precancerous cells;
2) increasing RUNX1 activity;
3) decreasing cancer-causing inflammation;
4) fixing or replacing RUNX1-mutated cells using cell or gene therapy.
4 Rational Therapeutic Approaches to Cancer Interception/Prevention
